Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 15.74M shares outstanding
USTevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology.
Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID.
The company is based in Warren, New Jersey.
Dr. Curtis Patton
Director
Dr. Keow Lin Goh
Director
Dr. Ryan Saadi
Co-Founder, Chief Executive Officer & Chairperson
Jeffrey Feike
Director
Employees
18
Country
US
Sector
Healthcare
Website
tevogen.com
Loading congressional disclosures…
based on 15.74M shares outstanding
US30d Avg
6.57K
60d Avg
7.42K
90d Avg
9.74K
